Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 13 22:11 ET

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Simply Wall StFeb 10 20:44 ET

Hong Kong Shares Edge Lower, Tracking U.S. Futures -- Market Talk

WSJFeb 6 20:40 ET

Hong Kong stocks movement | SINOPHARM (01099) falls nearly 3% as Institutions indicate the company's growth visibility is limited, expecting last year's net profit to decline by 9% year-on-year.

SINOPHARM (01099) dropped nearly 3%, as of the time of writing, down 2.97%, reported at 19.94 Hong Kong dollars, with a transaction amount of 33.4061 million Hong Kong dollars.

Zhitong FinanceFeb 2 21:28 ET

Daiwa: Downgraded SINOPHARM's rating to "Outperform the Market" and cut the Target Price to HKD 22.

Daiwa published a research report stating that the rating of SINOPHARM (01099) has been reduced from "Buy" to "Outperform," due to limited growth visibility and inconsistent domestic policy impacts. Meanwhile, the revenue forecasts for 2024 and 2025 have been downgraded by 8% and 11% respectively, indicating a year-on-year growth rate of either flat or 6%. The Target Price has been adjusted from 26 HKD to 22 HKD accordingly. The firm stated that it maintains a cautious outlook on the sales of SINOPHARM's Medical Device and retail pharmacy Business in the fourth quarter of 2024, expecting the group's overall revenue and Net income to grow year-on-year by 2% and decrease by 9% respectively, reaching 1.53 billion yuan and 2.7 billion yuan.

Sina Hong Kong StocksJan 23 02:59 ET

China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong FinanceJan 20 18:54 ET